BioNTech SE (NASDAQ:BNTX – Get Rating) – Investment analysts at SVB Leerink issued their Q1 2023 earnings per share estimates for BioNTech in a research report issued on Friday, July 29th. SVB Leerink analyst D. Graybosch expects that the company will post earnings per share of $7.02 for the quarter. SVB Leerink currently has a “Outperform” rating and a $224.00 target price on the stock. The consensus estimate for BioNTech’s current full-year earnings is $33.51 per share. SVB Leerink also issued estimates for BioNTech’s Q2 2023 earnings at $5.27 EPS, Q3 2023 earnings at $4.56 EPS, Q4 2023 earnings at $7.09 EPS, Q1 2024 earnings at ($0.88) EPS, Q2 2024 earnings at $0.56 EPS and FY2026 earnings at $9.34 EPS.
BioNTech (NASDAQ:BNTX – Get Rating) last released its earnings results on Monday, May 9th. The company reported $15.98 EPS for the quarter, beating the consensus estimate of $9.14 by $6.84. BioNTech had a net margin of 55.13% and a return on equity of 122.24%. The firm had revenue of $6.37 billion for the quarter, compared to analysts’ expectations of $4.50 billion. BioNTech’s quarterly revenue was up 211.2% on a year-over-year basis. During the same quarter last year, the company earned $5.29 EPS.
BioNTech Trading Up 0.1 %
BioNTech stock opened at $165.15 on Monday. BioNTech has a 12-month low of $117.08 and a 12-month high of $464.00. The stock has a market capitalization of $40.13 billion, a PE ratio of 2.87 and a beta of -0.09. The firm has a 50 day simple moving average of $153.24 and a 200-day simple moving average of $157.58. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.05 and a quick ratio of 4.93.
Institutional Trading of BioNTech
Several large investors have recently added to or reduced their stakes in the company. National Bank of Canada FI purchased a new position in shares of BioNTech during the fourth quarter valued at $36,000. Yousif Capital Management LLC acquired a new stake in BioNTech during the 4th quarter worth about $964,000. Mezzasalma Advisors LLC grew its stake in BioNTech by 2.4% during the 4th quarter. Mezzasalma Advisors LLC now owns 4,690 shares of the company’s stock valued at $1,209,000 after acquiring an additional 110 shares in the last quarter. Centaurus Financial Inc. purchased a new position in BioNTech during the 4th quarter valued at about $355,000. Finally, Astrantus Ltd acquired a new position in shares of BioNTech in the 4th quarter valued at about $516,000. 14.42% of the stock is owned by institutional investors and hedge funds.
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.
- Get a free copy of the StockNews.com research report on BioNTech (BNTX)
- Use These To Find Your Stock’s Support and Resistance Levels
- Is Boeing Stock is Ready for Lift-Off ?
- Elon Musk is Out, But Should You Be In Twitter Stock?
- 3 Earnings Announcements That Could Surprise
- Twitter’s Up For Third Week In A Row: What’s Next For The Stock?
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.